Sorrento Therape (SRNE)

NASDAQ
7.830
-0.250(-3.09%)
After Hours
8.000
+0.170(+2.171%)
- Real-time Data
  • Volume:
    3,388,979
  • Bid/Ask:
    8.000/8.050
  • Day's Range:
    7.830 - 8.080

SRNE Overview

Prev. Close
8.08
Day's Range
7.83-8.08
Revenue
51.03M
Open
8.01
52 wk Range
5.17-17.24
EPS
-1.17
Volume
3,388,979
Market Cap
2.33B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
5,559,961
P/E Ratio
-
Beta
2.4
1-Year Change
-18.73%
Shares Outstanding
298,099,574
Next Earnings Date
11 Nov 2021
What is your sentiment on Sorrento Therape?
or
Market is currently closed. Voting is open during market hours.

Sorrento Therape News

Sorrento Therape Analysis

  • 3 “Strong Buy” Stocks Showing Monster Growth
    • ByTipranks-

    We’re well into the second half of 2021, and with any luck at all we’ll soon see last year’s major headwinds fully relegated to the rear-view mirror. Even so, current

  • Vaccine Victory Lap
    • ByTalkmarkets-

    Monday the US stock market moved into further robust mode fueled by official FDA approval of the Pfizer and BioNTech COVID-19 vaccines. Will the momentum last through to Thursday...

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellNeutral
SummaryStrong SellStrong SellStrong SellStrong SellNeutral

Sorrento Therape Company Profile

Sorrento Therape Company Profile

Employees
502

Sorrento Therapeutics, Inc. is a clinical-stage and commercial biopharma company. The Company operates through two segments: Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T), antibody-drug conjugates (ADC), as well as bispecific antibody approaches. Additionally, Sorrento Therapeutics segment also includes Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system to potentially achieve improved efficacy and fewer adverse effects than standard parenteral immunotherapy. The Scilex segment is organized around its non-opioid pain management operations.

Read More
  • The chart hete has gone crazy. 🤣
    0
    • ikr. plus 300 percent
      0
    • it is reading pre-market 300+ percent up
      0
  • ******stock
    0
    • Told ya
      0
      • 😂great implosion
        0
    • About to implode
      0
      • What is happening with SRNE
        0
        • Easy buy here
          0
          • Isn't it a quick sand stock ?
            1
            • Will srne trend up continue?
              0
              • Yes, for sure. Prob to 23 -25 and stay there for a while
                0
              • Isn't it a quick sand stock ?
                0
            • nice w forming
              0
              • news is very good DOD trial, phase 3 covid trial can only go up although might be long term probably April time before significant price increase, thats my plan.
                0
                • What is the expectation
                  0
                  • where is the future of SRNE? Up or down?
                    0
                    • all depends on big news , of nonews then inthink 11 by the end of the yesr
                      0
                  • getting ready to take off
                    0
                    • just bought more! going to 20 soon
                      0
                      • they come down first sir and they come up after
                        0
                      • which platform do you use to buy stocks
                        0
                    • Buy now ! By friday 20+
                      2
                      • How can I update the blog? Last comment showing is dated 24 August
                        0
                        • Hello which platform do you use to buy stocks
                          0
                      • Whta is happening :(
                        0
                        • CFO asked to go
                          0
                        • Still heading down why?
                          0
                      • Buy
                        1
                        • $35 by December 2020best stock 2020
                          4
                          • Might go bankrupt before then
                            1
                        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.